key: cord-0911925-eok872bj authors: Mobasheri, Leila; Hossein Nasirpour, Mohammad; Masoumi, Elham; Foolady Azarnaminy, Afsaneh; Jafari, Mozhdeh; Esmaeili, Seyed-Alireza title: SARS-CoV-2 triggering autoimmune diseases date: 2022-04-05 journal: Cytokine DOI: 10.1016/j.cyto.2022.155873 sha: aef32a9b84e2b17bf9acf1051a4c2e126d5f68ba doc_id: 911925 cord_uid: eok872bj Autoimmunity, a hyperstimulation of immune system, can be caused by a variety of reasons. Viruses are thought to be important environmental elements that contribute to the development of autoimmune antibodies. It seems that viruses cause autoimmunity with mechanisms such as molecular mimicry, bystander activation of T cells, transient immunosuppression, and inflammation, which has also been seen in post-Covid-19 autoimmunity. Infection of respiratory epithelium by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), dysregulate the immune response, trigger both innate and acquired immunity that led to the immune system's hyper-activation, excessive cytokine secretion known as “cytokine storm,” and finally acute respiratory distress syndrome (ARDS) associated with high mortality. Any factor in the body that triggers chronic inflammation can contribute to autoimmune disease, which has been documented during the Covid-19 pandemic. It has been observed that some patients produce autoantibody and autoreactive CD4(+) and CD8(+) T cells, leading to the loss of self-tolerance. However, there is a scarcity of evidence defining the precise molecular interaction between the virus and the immune system to elicit autoreactivity. Here we present a review of the relevant immunological findings in Covid-19, and the current reports autoimmune disease associated with the disease. Beta-coronaviruses (β-CoVs) belong to the genus of coronaviruses (CoVs) and family of zoonotic viruses. After incidence of severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) in 2003 and 2012, respectively, the newest of β-CoVs appeared in December 2019 in Wuhan city, China, was named SARS-CoV-2 (1) . SARS-CoV-2 has been identified as the cause of coronavirus disease 2019 (Covid- 19) , defined as an acute inflammatory infectious disease (2) (3) (4) . Over 80 million cases of have been confirmed universally, at a ~2.2% case fatality rate that mostly happens in the 15-20% of the severe cases of the disease with bilateral interstitial pneumonia (5) . In these cases, acute respiratory distress syndrome (ARDS), characterized by the quick beginning of widespread inflammation in the lungs, is considered as the leading cause of mortality (4, 6-10). Both innate and acquired immunity play a crucial role in response to SARS-CoV-2 and a disease progression (11) . It has been shown that Covid-19 disrupts normal protective antiviral immunity, particularly in patients with comorbidities, old age, and specific genetic background through causing lymphopenia (CD4 + T, CD8 + T, NK, and B cell), reduction of regulatory T cells (Treg), overactivation of T cell, overproduction of pro-inflammatory cytokines (IL-2R, IL-1, IL-6, IL-8, IL-10, IL-17, and TNF-α), exhaustion of T cell, and an increase in antibodies (12) (13) (14) . Studies show that defects in immune tolerance and homeostasis mechanisms lead to inappropriate activation of the interferon pathway and autoinflammation (15, 16) . There is now broadly acknowledged that autoimmune disorders are linked to autoinflammatory conditions (17, 18) . Although, the precise etiology of such complicated diseases remain unclear (19) , various factors including genetic susceptibility (20) , epigenetic effects, the environmental stimuli such as microbial, fungal, parasitic, and viral pathogens can predispose a person to autoimmune disorders (21) (22) (23) (24) (25) . Viral infections can cause intolerance by different mechanisms, including molecular mimicry (cross-reacting epitope between pathogen-derived and the self-antigens), bystander killing (virus-specific CTLs migrating to the target tissues and exerting cytotoxicity), epitope spreading (polyclonal activation due to the constant presence of viral antigens driving immune-mediated injury), clearance deficiency and viral persistence that can increase the risk of autoreactivity. These factors contribute to autoinflammatory reactions and exacerbations of autoimmune disease (16, (26) (27) (28) (29) . Like as many viral infections (30) , SARS-CoV-2 can lead to various autoimmune symptoms (31) . By entering the upper respiratory tract, virus multiplies in the respiratory mucosa's epithelial cells. The immune system eradicates the virus. Otherwise, the virus reaches the lungs with the possibility of over-activation of the innate and acquired immune system, followed by the entry of antibodies into the bloodstream. The antibodies produced against the virus can reacted with the proteins expressed on human cells, causing systemic manifestations (32, 33) . Several autoimmune disorders such as Immune thrombocytopenic purpura (ITP), Guillian-Barrė syndrome (GBS), Miller Fisher syndrome (MFS), Kawasaki-like disease in children, etc have been recorded in connection with . Given the increasing mystery of SARS-COV.2 virus and its essential relationship to the autoimmune complications, we reviewed current advances in autoimmune conditions following COVID-19 disease. Entry and replication of SARS-CoV-2 in a host cell is mediated by the interaction of angiotensinconverting enzyme 2 (ACE-2) host receptor, expressed in respiratory epithelial cells, with the receptor-binding domain (RBD) region of virus Spike glycoprotein (S) (39) . Then antigenpresenting cells (APCs) such as dendritic cells, macrophages, and B cells can endocytose released viral particles and present peptide antigens to CD4 + T cells by MHC class II. Activated CD4 + T cells, as a central mediator, are involved in pro-inflammatory cytokines secretion, macrophage activation, CD8 + T cells priming, promoting B cells to antibody production and targeting the SARS-CoV-2 (40, 41) . The antibody often interacts misleadingly with the host surface proteins in a phenomenon called "Molecular mimicry" (Figure 1 ) (42) . It usually happens when microbial peptides share the same antigenic sequences with host self-proteins (43) . Several studies have suggested that molecular mimicry may play an important role in autoimmunity generation in Covid-19 (44, 45) . It has been shown that hexapeptides sequences of SARS-CoV-2 (nucleocapsid (N), membrane (M), ORF7b, ORF7a, ORF71a, ORF71b, especially S glycoprotein) shared similar sequence with human proteins that can cause a wide range of complications from pulmonary disorders, cardiac and vascular failure, neurological disorders to autoinflammatory syndrome and ADs (46, 47) . Hexapeptides of N, and surface glycoprotein of SARS-CoV-2 have shown notable similarity with three human proteins, namely DAB1, AIFM, and SURF1, which are involved in neurons development and mitochondrial metabolism (48) . Angileri et al. revealed the crossreactivity of SARS-COV-2 amino acid sequences with human proteins including OR7D4, PARP9, SLC12A6 on the plasma membrane of olfactory neurons, the cytoplasmic matrix of B cell and macrophage, endothelial cells of various organs, respectively, leading to a malfunction in target organs (44) . Also, Angileri et al. found Ankyrin 1 (ANK-1) amino acid sequence (323-LLLQY-327) similar to S glycoprotein of SARS-CoV-2 (752-LLLQY-756), describing autoimmune hemolytic anemia associated with SARS-CoV-2 disease (49) . Furthermore, shock protein (HSP)/chaperones with high grade of similarity in all organisms, can be targeted by the immune response, probably due to molecular mimicry. Cellular stress, followed by decreases in oxygen levels by SARS-CoV-2-induced pneumonia, can induce molecular chaperones to migrate to the plasma-cell membrane, probably after being modified and, consequently, can be recognized as foreign antigens by circulating antibodies made against cross-reactive microbial antigens, thus, creates the conditions for autoimmunity (32, 45) . Additionally, sequence analysis of the 41 human proteins associated with acute and chronic immune-mediated neuropathies showed that SARS-CoV-2 shares two immunologically relevant hexapeptides (KDKKKK and EIPKEE) with the human heat shock proteins 90 (HSP90B and HSP90B2) and 60 (HSP60), respectively, which are associated with Guillain-Barré syndrome, myasthenia gravis, and multiple sclerosis (MS) (42) . (53) (54) (55) . CD8+ T-cells showed a notable ability to clearance SARS-CoV-2 infected cells with long-lasting immunity (56) . Bystander killing in the eliminating infected cells is another probable mechanism to promote autoimmunity followed by COVID-19 ( Figure 1 ). Also,, during the clonal expansion of reactive T-cells to an infection, a significant proportion of self-reactive T-cells may be increased in Covid-19 (57) . In the pathogenesis of autoimmune disease cytokines may also play an essential role. SARS-CoV-2 infection stimulates the secretion of serum cytokines majorly TNF-α, IFN-β, IL-6, IL-1β, IL-17, and IL-18 (53) , leading to an aberrant innate and acquired immune response (58, 59) and loss of tolerance to self-antigens, ADs, and deterioration patients with ADs (60). CD4+ T-regulatory cells suppress the immunity at the end of an immune response, control immune homeostasis via inhibiting the pro-inflammatory function of effector T cells (61) . They identified by FOXPE expression as a specific transcription factor and also high levels of variable inhibitory molecules include CTLA-4, GITR, CD39, and CD73. T-regs can also be characterized based on the secretion of immunosuppressive cytokines that can prevent autoimmune phenomena, including TGF-beta, IL-10, and IL-35 (62) . Studies indicate the diminished and dysfunctional T-regs in severe Covid-19 patients (63, 64) . Besides, a proportion of Treg will shift their phenotype to Th17 cells under an inflammatory environment, which will enhance the inflammatory response and trigger neutrophils (65, 66) . So, The balance between these two cell populations is a hallmark factor to immune-homeostasis, and disturbance of this balance is known to be associated with ADs pathogenesis (67) . Additionally, IL-6, which is the most prominent cytokine produced in Covid-19 patients, inhibits CD4 + CD25 + FOXP3 T-reg cells, therefore attributing to the development of a various ADs (68) . Increased expression of inhibitory receptors (CD57, PD-1, and Tim-3) in CD8 + T cell, is associated with prolonged infections and T cell exhaustion has been observed in patients with Covid-19 (69) (70) (71) . The binding of PD-L1 to PD-1 in the surface of CD8 T cell, inhibits the proliferation of CD8 + T cell, inflammation, results in apoptosis of infiltrating lymphocytes, diminished cytotoxicity, and prevents autoimmune tissue-damaging (72) . T-cell exhaustion is a characteristic of chronic illness that prevents the immune response and encourages viral retention (73) . On the other hand, auto-reactive immune cells followed by a persistent chronic inflammatory response exert major autoimmune diseases (43) . Cañas CA et al, have put forward a hypothesis that the development of post-COVID-19 autoimmunity may can be a consequences of transient immunosuppression of both of innate and acquired immunity leading a lack of selftolerance and an insufficient process of immune reconstitution (74) . It seems that the immune response may not be well regulated in some infected individuals, paving the way for the development of secondary autoimmunity to SARS-CoV-2, which is summarized in Table 1 . Idiopathic thrombocytopenic purpura (ITP) is a hematological disorder affecting the total number of blood platelets and thrombocytopenia (platelet count < 100 × 10 9 /L, normal range 150-450 × 10 9 /L) (75) . Two-thirds of ITP cases can be secondary to infections that induce autoantibodies cross-reactive to glycoproteins IIb-IIIa or Ib on platelets and megakaryocytes, causing reduced longevity of circulating platelets and impaired platelet production (76) . The response to IVIG and corticosteroids therapy is a fair indicator of immune origin in thrombocytopenia and has a beneficial effect on excessive SRAS-CoV-2 inflammatory reactions. Graves' disease (GD) is an autoimmune hyper-thyroidismis, that onsets in the consequence of immune imbalance and development of auto-antibodies against the thyrotropin receptor (TSHR) (82) . Other antibodies, including thyroid peroxidase (TPO) and thyroglobulin (TG) antibodies, may be significantly elevated but are not specific to GD (82) . Administration of thiamazole and propranolol improves the symptoms and thyroid function in both cases (87). Multiple sclerosis (MS) is a Guillain Barré syndrome (GBS) is a worsening neuromuscular disorder that tends to destroy the nerves and leads to muscle paralysis (98) . tests showed no abnormalities in glucose levels and no results suggestive collagen disease, thyroid disease, or vitamin abnormalities (105, 106) . Although the role of antibodies in developing GBS has remains unclear, antibody-independent pathways such as hyper inflammation following macrophage activation and vascular endothelial damage of the brain may lead to neurological symptoms in patients with SARS-CoV-2 infection (107). Myasthenia gravis (MG) is an autoimmune disorder characterized by fluctuating fatigability and muscle weakness. MG can appear with extraocular muscle involvement as the initial symptom, usually progressing to other bulbar muscles and limb muscle groups, resulting in generalized MG. It may be associated with thymoma, and anti-neuromuscular junction autoantibodies, or it may appear without autoantibodies (108 (114) . According to the reviewed studies, the MG manifestation can be a particular complication of Covid-19 patients. However, further studies are needed to make a definitive statement and to find an exact link between the pathogenesis of Covid and myasthenia gravis. Systemic lupus erythematosus (SLE) is a clinically heterogeneous autoimmune disorder result from a multifaceted interaction of the immune system, genetics, and environmental factors (19, 115, 116) . SLE pathogenesis comprises of the inherent and adaptive immune systems, autoantibodies formation, complement system activation, cytokine dysregulation (especially interferons of type I) and disrupted apoptotic clearance (117) (118) (119) . symptoms. She received ceftazidime, vancomycin, azithromycin, hydroxychloroquine, steroids, and underwent plasmapheresis for a short time. She also evolved severe anemia and thrombocytopenia, which was resolved with supportive care and transfusions. She then developed thrombosis, raising concerns for antiphospholipid syndrome, and was started on anticoagulation. Unfortunately, on the seventeenth day of her hospitalization, she died of a cardiac arrest (121). Studies showed the gradually recognition of complications of SARS-CoV-2 infection. Although the respiratory system is affected mainly by the SARS-CoV-2, other organs, including gastrointestinal, hematopoietic, genitourinary, nervous, and cardiovascular systems, may even be affected without respiratory symptoms (122) (123) (124) (125) . COVID-19-related complications are either directly caused by the virus attack or indirectly due to the antiviral immune response (126, 127 ). An inadequate immune response can lead to spread of infection, and a strong immune response can lead to serious immunopathologic reactions, in some cases contributing to autoimmunity (128) . The relationship between autoimmunity and viral infection is often clarified by molecular mimicry, bystander activation, and viral persistence (129) . The SARS-CoV-2 infection could cause or simulate a type of organ-specific autoimmunity in predisposed patients, according to the serological, radiological, and histopathological similarities between Covid-19-associated ARDS and lung manifestations of connective tissue disease in a study (130) . Production of autoantibody, higher levels of IL-6 and TNF-α, increased inflammatory phenotypes of CD4 + T cells including Th1, Th17, and Th22, increased numbers of CD8+ T cells, and reduced numbers of Treg cells can contribute to the autoimmunity (131) . In addition to virus infections, vaccination can also be a cause of autoimmunity, as the increased risk of Guillain Barre syndrome following of influenza vaccine was reported (132) . The possible mechanisms that vaccines can induce autoimmune reactions are molecular mimicry and bystander activation (133) . Understanding molecular mimicry about SARS-CoV-2 peptide sequences and comprehensive human proteome researches can be effective in producing safe and high-quality vaccines (134) . Such studies are necessary to reduce the risk of acute autoimmune reactions to vaccination and the development of autoimmune diseases following COVID-19 disease. The authors declare no competing financial and non-financial interests. The current study is review article and manuscript complies with the Ethical Rules applicable for this journal. Infection of respiratory epithelium by virus trigger both innate and acquired immunity that led to the immune system's hyper-activation Therefore triggers chronic inflammation can contribute to autoimmune disease, Post-Covid-19 autoimmunity may be due to molecular mimicry, bystander activation of T cells, transient immunosuppression, and pro-inflammatory cytokines, which might complicate SARS-CoV-2 vaccination Leila Mobasheri, Elham Masoumi, Mozhdeh Jafari and Afsaneh Foolady participated in data collection and manuscript writing. Seyed-Alireza Esmaeili designed and drafted the article. All authors have fully read and approved the final manuscript. Current epidemiological and clinical features of COVID-19; a global perspective from China The epidemiology and clinical information about COVID-19 COVID-19: A global pandemic Coronavirus new variants: the mutations cause and the effect on the treatment and vaccination: Coronavirus new Variants: effect and treatments Predictive symptoms and comorbidities for severe COVID-19 and intensive care unit admission: a systematic review and meta-analysis COVID-19-associated acute respiratory distress syndrome: is a different approach to management warranted? The Lancet Respiratory Medicine Chinese parental awareness of Children's COVID-19 protective measures Health behaviors at the onset of the COVID-19 pandemic The impact of ACE2 genetic polymorphisms (rs2106809 and rs2074192) on gender susceptibility to COVID-19 infection and recovery: A systematic review The impact of lymphoid memory cells in different ages of COVID-19 patients Immune parameters and COVID-19 infection-associations with clinical severity and diseases prognosis COVID-19: immunopathogenesis and Immunotherapeutics Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 T cell response in patients with COVID-19 Editorial overview: Autoimmunity: New genomics approaches are improving our understanding of autoimmunity Viruses and autoimmunity: a review on the potential interaction and molecular mechanisms The innate immune perspective of autoimmune and autoinflammatory conditions Immunotherapy of multisystem inflammatory syndrome in children (MIS-C) following COVID-19 through mesenchymal stem cells Curcumin: A natural modulator of immune cells in systemic lupus erythematosus Frequencies of HLA-A, B and DRB1 alleles in a large normal population living in the city of Mashhad, Northeastern Iran. Iranian journal of basic medical sciences Expert panel workshop consensus statement on the role of the environment in the development of autoimmune disease The role of epigenetics in autoimmune/inflammatory disease The role of genetic factors in autoimmune disease: implications for environmental research Generation of tolerogenic dendritic cells using Lactobacillus rhamnosus and Lactobacillus delbrueckii as tolerogenic probiotics Vitamin D3 alters the expression of toll-like receptors in peripheral blood mononuclear cells of patients with systemic lupus erythematosus The role of defective clearance of apoptotic cells in systemic autoimmunity Neutrophil extracellular traps: double-edged swords of innate immunity Amelioration of regulatory T cells by Lactobacillus delbrueckii and Lactobacillus rhamnosus in pristane-induced lupus mice model In vivo study: Th1-Th17 reduction in pristane-induced systemic lupus erythematosus mice after treatment with tolerogenic Lactobacillus probiotics Autoimmune and rheumatic musculoskeletal diseases as a consequence of SARS-CoV-2 infection and its treatment Does SARS-CoV-2 trigger stress-induced autoimmunity by molecular mimicry? A hypothesis Clinical-forensic autopsy findings to defeat COVID-19 disease: a literature review Miller Fisher Syndrome and polyneuritis cranialis in COVID-19 Guillain-Barré syndrome associated with SARS-CoV-2 infection: causality or coincidence? The Lancet Neurology An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study. The Lancet Bruxism as a clinical indicator of mental ilness: lessons from the COVID-19 to the future! Archives of Clinical Psychiatry Immunopathogenesis of COVID-19 and early immunomodulators Immunology of COVID-19: current state of the science Mesenchymal stem/stromal cells as a vehicle for cytokine delivery: an emerging approach for tumor immunotherapy SARS-CoV-2 and Guillain-Barré syndrome: molecular mimicry with human heat shock proteins as potential pathogenic mechanism Molecular mimicry as a mechanism of autoimmune disease Human molecular chaperones share with SARS-CoV-2 antigenic epitopes potentially capable of eliciting autoimmunity against endothelial cells: possible role of molecular mimicry in COVID-19 Molecular mimicry between SARS-CoV-2 spike glycoprotein and mammalian proteomes: implications for the vaccine From anti-SARS-CoV-2 immune responses to COVID-19 via molecular mimicry Molecular mimicry between SARS-CoV-2 and respiratory pacemaker neurons Is molecular mimicry the culprit in the autoimmune hemolytic anemia affecting COVID-19 patients? Potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases Covid-19 and autoimmunity Follistatin-like protein 1 is elevated in systemic autoimmune diseases and correlated with disease activity in patients with rheumatoid arthritis Pathological findings of COVID-19 associated with acute respiratory distress syndrome. The Lancet respiratory medicine Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications The known unknowns of T cell immunity to COVID-19 T-cell dysregulation in COVID-19. Biochemical and Biophysical Research Communications Cytokine Release Syndrome in COVID-19 Patients, A New Scenario for an Old Concern: The Fragile Balance between Infections and Autoimmunity Probiotics with ameliorating effects on the severity of skin inflammation in psoriasis: Evidence from experimental and clinical studies The potential similarities of COVID-19 and autoimmune disease pathogenesis and therapeutic options: new insights approach Regulatory T cells (TREG) and their roles in immune system with respect to immunopathological disorders Phenotypical characterization of regulatory T cells in humans and rodents Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clinical Infectious Diseases Regulatory T cells for treating patients with covid-19 and acute respiratory distress syndrome: two case reports Cytokines in autoimmunity: role in induction, regulation, and treatment The plasticity of human Treg and Th17 cells and its role in autoimmunity Balancing inflammation: the link between Th17 and regulatory T cells Cytokine storm and COVID-19: a chronicle of proinflammatory cytokines Marked T cell activation, senescence, exhaustion and skewing towards TH17 in patients with COVID-19 pneumonia CoViD-19 Immunopathology and Immunotherapy Survivin a pivotal antiapoptotic protein in rheumatoid arthritis On the use of immune checkpoint inhibitors in patients with viral infections including COVID-19 T-cell exhaustion, co-stimulation and clinical outcome in autoimmunity and infection The triggering of post-COVID-19 autoimmunity phenomena could be associated with both transient immunosuppression and an inappropriate form of immune reconstitution in susceptible individuals Emerging Concepts in Immune Thrombocytopenia Idiopathic thrombocytopenic purpura (ITP)-new era for an old disease Idiopathic thrombocytopenic purpura COVID-19-associated immune thrombocytopenia Severe immune thrombocytopenia in a critically ill COVID-19 patient ITP flare with mild COVID-19 infection in pregnancy: A case report Acute immune thrombocytopaenic purpura in a patient with COVID-19 and decompensated cirrhosis Current concepts in Graves' disease. Therapeutic advances in endocrinology and metabolism Delineating the autoimmune mechanisms in Graves' disease. Immunologic research Thyroid disorders and SARS-CoV-2 infection: From pathophysiological mechanism to patient management Impact of COVID-19 on the thyroid gland: an update SARS-CoV-2-related atypical thyroiditis SARS-COV-2 as a trigger for autoimmune disease: report of two cases of Graves' disease after COVID-19 Immunopathogenesis of multiple sclerosis Immunoregulatory effects of tolerogenic probiotics in multiple sclerosis Immunoregulatory effects of tolerogenic probiotics in multiple sclerosis Immunopathogenesis of multiple sclerosis. International review of neurobiology Fingolimod immune effects beyond its sequestration ability Viral-induced suppression of self-reactive T cells: Lessons from neurotropic coronavirus-induced demyelination Does upper respiratory infection exacerbate symptoms of multiple sclerosis? Multiple sclerosis following SARS-CoV-2 infection. Multiple sclerosis and related disorders Neuromyelitis optica spectrum disorders: An update Neuromyelitis optica spectrum disorder after presumed coronavirus (COVID-19) infection: a case report. Multiple sclerosis and related disorders Guillain Barre syndrome Post Vaccination Guillain Barre Syndrome: A Case Report The rapid development and early success of Covid 19 vaccines have raised hopes for accelerating the cancer treatment mechanism Guillain-Barré syndrome: pathogenesis, diagnosis, treatment and prognosis Guillain-Barré syndrome in the COVID-19 era: just an occasional cluster Guillain-Barré syndrome associated with SARS-CoV-2 Guillain-Barré syndrome associated with COVID-19 disease Guillain-Barré syndrome after COVID-19 in Japan Importance of Vitamin D3 in COVID-19 Patients Neurological aspects of SARS-CoV-2 infection: mechanisms and manifestations Myasthenia gravis: a review. Autoimmune diseases Clinical features, pathogenesis, and treatment of myasthenia gravis: a supplement to the Guidelines of the German Neurological Society Inflammation and Epstein-Barr virus infection are common features of myasthenia gravis thymus: possible roles in pathogenesis Myasthenia gravis associated with SARS-CoV-2 infection Postinfectious onset of myasthenia gravis in a COVID-19 patient New onset of ocular myasthenia gravis in a patient with COVID-19: a novel case report and literature review Systemic lupus erythematosus: An overview of the disease pathology and its management Tolerogenic probiotics: potential immunoregulators in Systemic Lupus Erythematosus Systemic lupus erythematosus: diagnosis and clinical management The immunomodulatory effects of mesenchymal stromal cell-based therapy in human and animal models of systemic lupus erythematosus Lactobacillus rhamnosus and Lactobacillus delbrueckii ameliorate the expression of miR-155 and miR-181a in SLE patients Systemic lupus erythematosus and varicella-like rash following COVID-19 in a previously healthy patient Concomitant new diagnosis of systemic lupus erythematosus and COVID-19 with possible antiphospholipid syndrome. Just a coincidence? A case report and review of intertwining pathophysiology New understanding of the damage of SARS-CoV-2 infection outside the respiratory system Recurrent Acute Pancreatitis in a Patient with COVID-19 Brief symptom inventory: Reporting Brazilian populational parameters during COVID-19 pandemics Covid-19 and its impact on livelihood: An Indian perspective Autoimmunity as the comet tail of COVID-19 pandemic Pharmacological and Radiological Study of Patients with COVID-19 in Iran Immunemediated approaches against COVID-19 Molecular mimicry, bystander activation, or viral persistence: infections and autoimmune disease COVID-19-induced acute respiratory failure: an exacerbation of organ-specific autoimmunity? medRxiv Emerging concepts in immune thrombocytopenia Influenza vaccination and Guillain Barre syndrome☆ Vaccination and autoimmune diseases: is prevention of adverse health effects on the horizon? Covid-19: Vaccine candidate may be more than 90% effective, interim results indicate The authors appreciate the cooperation of Mashhad University of Medical Sciences. The dataset(s) supporting the conclusions of this article is (are) included within the article (and its additional file(s)). The authors appreciate the cooperation of Mashhad University of Medical Sciences. ☒ The all of authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.☒The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: